Tech Company Financing Transactions
Arpeggio Bio Funding Round
Arpeggio Bio secured a $17 million Series A financing round on 9/7/2022. Investors included BuildersVC, ATEM Capital and Fifty Years.
Transaction Overview
Company Name
Announced On
9/7/2022
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
BuildersVC (Lead Investor)
private investors (Alice Zhang)
private investors (Matthew De Silva)
private investors (Milad Alucozai)
Proceeds Purpose
The company intends to use the funds to advance its drug pipeline as well as its transcription-monitoring technologies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
596 University of Colorado
Boulder, CO 80309
USA
Boulder, CO 80309
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Our technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug's function and guide therapeutic development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joey Azofeifa
Chief Operating Officer
Laura Norris
Founder
Timothy Read
Browse more venture capital transactions:
Prev: 9/7/2022: Localyze venture capital transaction
Next: 9/7/2022: ITSBLOC venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs